

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 March 2002 (07.03.2002)

PCT

(10) International Publication Number
WO 02/18596 A1

(51) International Patent Classification⁷: **C12N 15/31**,
15/77, C12P 13/04, 13/08 // C12R 1/15

(DE). **MARX, Achim**; Altenbrede 4B, 33613 Bielefeld
(DE).

(21) International Application Number: PCT/EP01/08387

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 20 July 2001 (20.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
100 42 741.3 31 August 2000 (31.08.2000) DE
101 08 841.8 23 February 2001 (23.02.2001) DE

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: **DEGUSSA AG** [DE/DE]; Bennigsenplatz 1, 40474 Düsseldorf (DE).


(72) Inventors: **MÖCKEL, Bettina**; Benrodestrasse 35, 40597 Düsseldorf (DE). **HERMANN, Thomas**; Zirkonstrasse 8, 33739 Bielefeld (DE). **FARWICK, Mike**; Gustav-Adolf-Strasse 11, 33615 Bielefeld (DE). **PFEFFERLE, Walter**; Jahnstrasse 33, 33790 Halle (Westf.)

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

[Continued on next page]

(54) Title: CITB GENE FROM CORYNEBACTERIA AND USE THEREOF IN SYNTHESIS OF L-AMINO ACIDS



(57) Abstract: The invention provides nucleotide sequences from coryneform bacteria which code for the citB gene and a process for the fermentative preparation of amino acids, in particular L-lysine, by attenuation of the citB gene. The citB gene codes for the citB protein, which is a transcription regulator of a two-component system.



WO 02/18596 A1



-
- *entirely in electronic form (except for this front page) and available upon request from the International Bureau*
 - *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

CITB GENE FROM CORYNEBACTERIA AND USE THEREOF IN SYNTHESIS OF L-AMINO ACIDS

Field of the Invention

The invention provides nucleotide sequences from coryneform bacteria which code for the citB gene and a process for the fermentative preparation of amino acids, in particular L-lysine, by attenuation of the citB gene. The citB gene codes for the CitB protein, which is a transcription regulator of a two-component system.

Prior Art

10 L-Amino acids, in particular L-lysine, are used in human medicine and in the pharmaceuticals industry, in the foodstuffs industry and very particularly in animal nutrition.

It is known that amino acids are prepared by fermentation from strains of coryneform bacteria, in particular Corynebacterium glutamicum. Because of their great importance, work is constantly being undertaken to improve the preparation processes. Improvements to the process can relate to fermentation measures, such as, for example, stirring and supply of oxygen, or the composition of the nutrient media, such as, for example, the sugar concentration during the fermentation, or the working up to the product form by, for example, ion exchange chromatography, or the intrinsic output properties of the microorganism itself.

Methods of mutagenesis, selection and mutant selection are used to improve the output properties of these microorganisms. Strains which are resistant to antimetabolites or are auxotrophic for metabolites of regulatory importance and which produce amino acids are obtained in this manner.

Methods of the recombinant DNA technique have also been employed for some years for improving the strain of *Corynebacterium* strains which produce L-amino acids.

Object of the Invention

- 5 The inventors had the object of providing new measures for improved fermentative preparation of amino acids, in particular L-lysine.

Summary of the Invention

- 10 If L-lysine or lysine are mentioned in the following, this also means the salts, such as e. g. lysine monohydrochloride or lysine sulfate.

The invention provides an isolated polynucleotide from coryneform bacteria, comprising a polynucleotide sequence which codes for the citB gene chosen from the group
15 consisting of

- a) polynucleotide which is identical to the extent of at least 70 % to a polynucleotide which codes for a polypeptide which comprises the amino acid sequence of SEQ ID No. 2,
- 20 b) polynucleotide which codes for a polypeptide which comprises an amino acid sequence which is identical to the extent of at least 70 % to the amino acid sequence of SEQ ID No. 2,
- c) polynucleotide which is complementary to the
25 polynucleotides of a) or b), and
- d) polynucleotide comprising at least 15 successive nucleotides of the polynucleotide sequence of a), b) or c),

the polypeptide preferably having the activity of the citB
30 protein.

The invention also provides the abovementioned polynucleotide, this preferably being a DNA which is capable of replication, comprising:

- (i) the nucleotide sequence shown in SEQ ID No.1 or
- 5 (ii) at least one sequence which corresponds to sequence (i) within the range of the degeneration of the genetic code, or
- (iii) at least one sequence which hybridizes with the sequences complementary to sequences (i) or (ii),
10 and optionally
- (iv) sense mutations of neutral function in (i).

The invention also provides:

a polynucleotide, in particular DNA, which is capable of replication and comprises the nucleotide sequence as
15 shown in SEQ ID No.1;

a polynucleotide which codes for a polypeptide which comprises the amino acid sequence as shown in SEQ ID No. 2;

a vector containing parts of the polynucleotide according
20 to the invention, at least 15 successive nucleotides of the sequence claimed

and coryneform bacteria in which the citB gene is attenuated, in particular by an insertion or deletion.

The invention also provides polynucleotides which
25 substantially comprise a polynucleotide sequence, which are obtainable by screening by means of hybridization of a corresponding gene library of a coryneform bacterium, which comprises the complete gene or parts thereof, with a probe which comprises the sequence of the polynucleotide

according to the invention or a fragment thereof, and isolation of the polynucleotide sequence mentioned.

Detailed Description of the Invention

Polynucleotides comprising the sequences according to the invention are suitable as hybridization probes for RNA, 5 cDNA and DNA, in order to isolate, in the full length, nucleic acids or polynucleotides or genes which code for the CitB protein or to isolate those nucleic acids or polynucleotides or genes which have a high similarity with 10 the sequence of the citB gene. They are also suitable for incorporation into so-called "arrays", "micro arrays" or "DNA chips" in order to detect and determine the corresponding polynucleotides.

Polynucleotides comprising the sequences according to the invention are furthermore suitable as primers with the aid 15 of which DNA of genes which code for the CitB protein can be prepared by the polymerase chain reaction (PCR).

Such oligonucleotides which serve as probes or primers comprise at least 30, preferably at least 20, very 20 particularly preferably at least 15 successive nucleotides. Oligonucleotides which have a length of at least 40 or 50 nucleotides are also suitable.

"Isolated" means separated out of its natural environment.

"Polynucleotide" in general relates to polyribonucleotides 25 and polydeoxyribonucleotides, it being possible for these to be non-modified RNA or DNA or modified RNA or DNA.

The polynucleotides according to the invention include a polynucleotide according to SEQ ID No. 1 or a fragment prepared therefrom and also those which are at least 70 %, 30 preferably at least 80 % and in particular at least 90 % to 95 % identical to the polynucleotide according to SEQ ID No. 1 or a fragment prepared therefrom.

"Polypeptides" are understood as meaning peptides or proteins which comprise two or more amino acids bonded via peptide bonds.

The polypeptides according to the invention include a
5 polypeptide according to SEQ ID No. 2, in particular those with the biological activity of the CitB protein, and also those which are at least 70 %, preferably at least 80 % and in particular at least 90 % to 95 % identical to the polypeptide according to SEQ ID No. 2 and have the activity
10 mentioned.

The invention moreover provides a process for the fermentative preparation of amino acids, in particular L-lysine, using coryneform bacteria which in particular already produce amino acids, and in which the nucleotide
15 sequences which code for the citB gene are attenuated, in particular eliminated or expressed at a low level.

The term "attenuation" in this connection describes the reduction or elimination of the intracellular activity of one or more enzymes (proteins) in a microorganism which are
20 coded by the corresponding DNA, for example by using a weak promoter or using a gene or allele which codes for a corresponding enzyme with a low activity or inactivates the corresponding gene or enzyme (protein), and optionally combining these measures.

25 The microorganisms which the present invention provides can prepare amino acids, in particular L-lysine, from glucose, sucrose, lactose, fructose, maltose, molasses, starch, cellulose or from glycerol and ethanol. They can be representatives of coryneform bacteria, in particular of
30 the genus Corynebacterium. Of the genus Corynebacterium, there may be mentioned in particular the species Corynebacterium glutamicum, which is known among experts for its ability to produce L-amino acids.

Suitable strains of the genus *Corynebacterium*, in particular of the species *Corynebacterium glutamicum* (*C. glutamicum*), are in particular the known wild-type strains

- 5 *Corynebacterium glutamicum* ATCC13032
- Corynebacterium acetoglutamicum* ATCC15806
- Corynebacterium acetoacidophilum* ATCC13870
- Corynebacterium melassecola* ATCC17965
- Corynebacterium thermoaminogenes* FERM BP-1539
- Brevibacterium flavum* ATCC14067
- 10 *Brevibacterium lactofermentum* ATCC13869 and
- Brevibacterium divaricatum* ATCC14020

or L-amino acid-producing mutants or strains prepared therefrom, such as, for example, the L-lysine-producing strains

- 15 *Corynebacterium glutamicum* FERM-P 1709
- Brevibacterium flavum* FERM-P 1708
- Brevibacterium lactofermentum* FERM-P 1712
- Corynebacterium glutamicum* FERM-P 6463
- Corynebacterium glutamicum* FERM-P 6464
- 20 *Corynebacterium glutamicum* DM58-1
- Corynebacterium glutamicum* DG52-5
- Corynebacterium glutamicum* DSM 5715 and
- Corynebacterium glutamicum* DSM 12866

- 25 The inventors have succeeded in isolating the new *citB* gene of *C. glutamicum* which codes for the CitB protein, which is a transcription regulator of a two-component system.

- To isolate the *citB* gene or also other genes of *C. glutamicum*, a gene library of this microorganism is first set up in *Escherichia coli* (*E. coli*). The setting up of gene libraries is described in generally known textbooks and handbooks. The textbook by Winnacker: *Gene und Klone, Eine Einführung in die Gentechnologie* (Verlag Chemie, Weinheim, Germany, 1990), or the handbook by Sambrook et
- 30

al.: Molecular Cloning, A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1989) may be mentioned as an example. A well-known gene library is that of the *E. coli* K-12 strain W3110 set up in λ vectors by Kohara et al.

5 (Cell 50, 495 -508 (1987)). Bathe et al. (Molecular and General Genetics, 252:255-265, 1996) describe a gene library of *C. glutamicum* ATCC13032, which was set up with the aid of the cosmid vector SuperCos I (Wahl et al., 1987, Proceedings of the National Academy of Sciences USA,
10 84:2160-2164) in the *E. coli* K-12 strain NM554 (Raleigh et al., 1988, Nucleic Acids Research 16:1563-1575). Börmann et al. (Molecular Microbiology 6(3), 317-326) (1992) in turn describe a gene library of *C. glutamicum* ATCC13032 using the cosmid pH79 (Hohn and Collins, 1980, Gene 11, 291-
15 298).

To prepare a gene library of *C. glutamicum* in *E. coli* it is also possible to use plasmids such as pBR322 (Bolivar, 1979, Life Sciences, 25, 807-818) or pUC9 (Vieira et al., 1982, Gene, 19:259-268). Suitable hosts are, in particular,
20 those *E. coli* strains which are restriction- and recombination-defective, such as, for example, the strain DH5 α (Jeffrey H. Miller: "A Short Course in Bacterial Genetics, A Laboratory Manual and Handbook for *Escherichia coli* and Related Bacteria", Cold Spring Harbour Laboratory
25 Press, 1992).

The long DNA fragments cloned with the aid of cosmids or other λ -vectors can then be subcloned in turn into the usual vectors suitable for DNA sequencing.

Methods of DNA sequencing are described, inter alia, by
30 Sanger et al. (Proceedings of the National Academy of Sciences of the United States of America USA, 74:5463-5467, 1977).

The resulting DNA sequences can then be investigated with known algorithms or sequence analysis programs, such as

e.g. that of Staden (Nucleic Acids Research 14, 217-232(1986)), that of Marck (Nucleic Acids Research 16, 1829-1836 (1988)) or the GCG program of Butler (Methods of Biochemical Analysis 39, 74-97 (1998)).

5 The new DNA sequence of *C. glutamicum* which codes for the *citB* gene and which, as SEQ ID No. 1, is a constituent of the present invention has been obtained in this manner. The amino acid sequence of the corresponding protein has
10 the methods described above. The resulting amino acid sequence of the *citB* gene product is shown in SEQ ID No. 2.

Coding DNA sequences which result from SEQ ID No. 1 by the degeneracy of the genetic code are also a constituent of the invention. In the same way, DNA sequences which
15 hybridize with SEQ ID No. 1 or parts of SEQ ID No. 1 are a constituent of the invention. Conservative amino acid exchanges, such as e.g. exchange of glycine for alanine or of aspartic acid for glutamic acid in proteins, are
20 furthermore known among experts as "sense mutations" which do not lead to a fundamental change in the activity of the protein, i.e. are of neutral function. It is furthermore known that changes on the N and/or C terminus of a protein cannot substantially impair or can even stabilize the
25 function thereof. Information in this context can be found by the expert, inter alia, in Ben-Bassat et al. (Journal of Bacteriology 169:751-757 (1987)), in O'Regan et al. (Gene 77:237-251 (1989)), in Sahin-Toth et al. (Protein Sciences 3:240-247 (1994)), in Hochuli et al. (Bio/Technology 6:1321-1325 (1988)) and in known textbooks of genetics and
30 molecular biology. Amino acid sequences which result in a corresponding manner from SEQ ID No. 2 are also a constituent of the invention.

Finally, DNA sequences which are prepared by the polymerase chain reaction (PCR) using primers which result from SEQ ID
35 No. 1 are a constituent of the invention. Such

oligonucleotides typically have a length of at least 15 nucleotides.

Instructions for identifying DNA sequences by means of hybridization can be found by the expert, *inter alia*, in the handbook "The DIG System Users Guide for Filter Hybridization" from Boehringer Mannheim GmbH (Mannheim, Germany, 1993) and in Liebl et al. (International Journal of Systematic Bacteriology 41: 255-260 (1991)). The hybridization takes place under stringent conditions, that is to say only hybrids in which the probe and target sequence, i. e. the polynucleotides treated with the probe, are at least 70 % identical are formed. It is known that the stringency of the hybridization, including the washing steps, is influenced or determined by varying the buffer composition, the temperature and the salt concentration. The hybridization reaction is preferably carried out under a relatively low stringency compared with the washing steps (Hybaid Hybridisation Guide, Hybaid Limited, Teddington, UK, 1996). A 5x SSC buffer at a temperature of approx. 50 - 68°C, for example, can be employed for the hybridization reaction. Probes can also hybridize here with polynucleotides which are less than 70 % identical to the sequence of the probe. Such hybrids are less stable and are removed by washing under stringent conditions. This can be achieved, for example, by lowering the salt concentration to 2x SSC and optionally subsequently 0.5x SSC (The DIG System User's Guide for Filter Hybridisation, Boehringer Mannheim, Mannheim, Germany, 1995) a temperature of approx. 50 - 68°C being established. Polynucleotide fragments which are, for example, at least 70 % or at least 80 % or at least 90 % to 95 % identical to the sequence of the probe employed can be isolated by increasing the hybridization temperature stepwise from 50 to 68°C in steps of approx. 1 - 2°C. Further instructions on hybridization are obtainable on the market in the form of so-called kits

(e.g. DIG Easy Hyb from Roche Diagnostics GmbH, Mannheim, Germany, Catalogue No. 1603558).

Instructions for amplification of DNA sequences with the aid of the polymerase chain reaction (PCR) can be found by
5 the expert, inter alia, in the handbook by Gait: Oligonucleotide Synthesis: A Practical Approach (IRL Press, Oxford, UK, 1984) and in Newton and Graham: PCR (Spektrum Akademischer Verlag, Heidelberg, Germany, 1994).

In the work on the present invention, it has been found
10 that coryneform bacteria produce amino acids, in particular L-lysine, in an improved manner after attenuation of the citB gene.

To achieve an attenuation, either the expression of the citB gene or the catalytic properties of the enzyme protein
15 can be reduced or eliminated. The two measures can optionally be combined.

The reduction in gene expression can take place by suitable culturing or by genetic modification (mutation) of the signal structures of gene expression. Signal structures of
20 gene expression are, for example, repressor genes, activator genes, operators, promoters, attenuators, ribosome binding sites, the start codon and terminators. The expert can find information on this e.g. in the patent application WO 96/15246, in Boyd and Murphy (Journal of
25 Bacteriology 170: 5949 (1988)), in Voskuil and Chambliss (Nucleic Acids Research 26: 3548 (1998)), in Jensen and Hammer (Biotechnology and Bioengineering 58: 191 (1998)), in Pátek et al. (Microbiology 142: 1297 (1996)), Vasicova et al. (Journal of Bacteriology 181: 6188 (1999)) and in
30 known textbooks of genetics and molecular biology, such as e.g. the textbook by Knippers ("Molekulare Genetik", 6th edition, Georg Thieme Verlag, Stuttgart, Germany, 1995) or that by Winnacker ("Gene und Klone", VCH Verlagsgesellschaft, Weinheim, Germany, 1990).

Mutations which lead to a change or reduction in the catalytic properties of enzyme proteins are known from the prior art; examples which may be mentioned are the works by Qiu and Goodman (Journal of Biological Chemistry 272: 8611-8617 (1997)), Sugimoto et al. (Bioscience Biotechnology and Biochemistry 61: 1760-1762 (1997)) and Möckel ("Die Threonindehydratase aus Corynebacterium glutamicum: Aufhebung der allosterischen Regulation und Struktur des Enzyms", Reports from the Jülich Research Centre, Jül-2906, ISSN09442952, Jülich, Germany, 1994). Summarizing descriptions can be found in known textbooks of genetics and molecular biology, such as e.g. that by Hagemann ("Allgemeine Genetik", Gustav Fischer Verlag, Stuttgart, 1986).

Possible mutations are transitions, transversions, insertions and deletions. Depending on the effect of the amino acid exchange on the enzyme activity, missense mutations or nonsense mutations are referred to. Insertions or deletions of at least one base pair (bp) in a gene lead to frame shift mutations, as a consequence of which incorrect amino acids are incorporated or translation is interrupted prematurely. Deletions of several codons typically lead to a complete loss of the enzyme activity. Instructions on generation of such mutations are prior art and can be found in known textbooks of genetics and molecular biology, such as e.g. the textbook by Knippers ("Molekulare Genetik", 6th edition, Georg Thieme Verlag, Stuttgart, Germany, 1995), that by Winnacker ("Gene und Klone", VCH Verlagsgesellschaft, Weinheim, Germany, 1990) or that by Hagemann ("Allgemeine Genetik", Gustav Fischer Verlag, Stuttgart, 1986).

A common method of mutating genes of *C. glutamicum* is the method of gene disruption and gene replacement described by Schwarzer and Pühler (Bio/Technology 9, 84-87 (1991)).

In the method of gene disruption a central part of the coding region of the gene of interest is cloned in a plasmid vector which can replicate in a host (typically *E. coli*), but not in *C. glutamicum*. Possible vectors are, for example, pSUP301 (Simon et al., Bio/Technology 1, 784-791 (1983)), pK18mob or pK19mob (Schäfer et al., Gene 145, 69-73 (1994)), pK18mobsacB or pK19mobsacB (Jäger et al., Journal of Bacteriology 174: 5462-65 (1992)), pGEM-T (Promega corporation, Madison, WI, USA), pCR2.1-TOPO (Shuman (1994). Journal of Biological Chemistry 269:32678-84; US Patent 5,487,993), pCR®Blunt (Invitrogen, Groningen, Holland; Bernard et al., Journal of Molecular Biology, 234: 534-541 (1993)) or pEM1 (Schrumpf et al., 1991, Journal of Bacteriology 173:4510-4516). The plasmid vector which contains the central part of the coding region of the gene is then transferred into the desired strain of *C. glutamicum* by conjugation or transformation. The method of conjugation is described, for example, by Schäfer et al. (Applied and Environmental Microbiology 60, 756-759 (1994)). Methods for transformation are described, for example, by Thierbach et al. (Applied Microbiology and Biotechnology 29, 356-362 (1988)), Dunican and Shivnan (Bio/Technology 7, 1067-1070 (1989)) and Tauch et al. (FEMS Microbiological Letters 123, 343-347 (1994)). After homologous recombination by means of a "cross-over" event, the coding region of the gene in question is interrupted by the vector sequence and two incomplete alleles are obtained, one lacking the 3' end and one lacking the 5' end. This method has been used, for example, by Fitzpatrick et al. (Applied Microbiology and Biotechnology 42, 575-580 (1994)) to eliminate the *recA* gene of *C. glutamicum*.

In the method of gene replacement, a mutation, such as e.g. a deletion, insertion or base exchange, is established in vitro in the gene of interest. The allele prepared is in turn cloned in a vector which is not replicative for *C. glutamicum* and this is then transferred into the desired

host of *C. glutamicum* by transformation or conjugation. After homologous recombination by means of a first "cross-over" event which effects integration and a suitable second "cross-over" event which effects excision in the target
5 gene or in the target sequence, the incorporation of the mutation or of the allele is achieved. This method was used, for example, by Peters-Wendisch et al. (Microbiology 144, 915 - 927 (1998)) to eliminate the *pyc* gene of *C. glutamicum* by a deletion.

- 10 A deletion, insertion or a base exchange can be incorporated into the *citB* gene in this manner.

In addition, it may be advantageous for the production of L-amino acids, in particular L-lysine, to enhance, in particular to over-express, one or more enzymes of the
15 particular biosynthesis pathway, of glycolysis, of anaplerosis, of the citric acid cycle, of the pentose phosphate cycle, of amino acid export and optionally regulatory proteins, in addition to attenuation of the *citB* gene.

- 20 The term "enhancement" in this connection describes the increase in the intracellular activity of one or more enzymes (proteins) in a microorganism which are coded by the corresponding DNA, for example by increasing the number of copies of the gene or genes, using a potent promoter or
25 using a gene or allele which codes for a corresponding enzyme (protein) having a high activity, and optionally combining these measures.

Thus, for example, for the preparation of L-lysine, at the same time one or more of the genes chosen from the group
30 consisting of

- the *dapA* gene which codes for dihydrodipicolinate synthase (EP-B 0 197 335),

- the gap gene which codes for glyceraldehyde 3-phosphate dehydrogenase (Eikmanns (1992), Journal of Bacteriology 174:6076-6086),
- the zwf gene which codes for glucose 6-phosphate
5 dehydrogenase (JP-A-09224661),
- the pyc gene which codes for pyruvate carboxylase (DE-A-198 31 609),
- the lysE gene which codes for lysine export (DE-A-195 48 222)
- 10 • the lysC gene which codes for a feed back resistant aspartate kinase (EP-B-0387527; EP-A-0699759; WO 00/63388), or
- the zwal gene which codes for the Zwal protein (DE: 199 59 328.0, DSM 13115)
- 15 can be enhanced, in particular over-expressed.

It may furthermore be advantageous for the production of amino acids, in particular L-lysine, in addition to the attenuation of the citB gene, for one or more of the genes chosen from the group consisting of

- 20 • the pck gene which codes for phosphoenol pyruvate carboxykinase (DE 199 50 409.1, DSM 13047),
- the pgi gene which codes for glucose 6-phosphate isomerase (US 09/396,478, DSM 12969),
- the poxB gene which codes for pyruvate oxidase
25 (DE:1995 1975.7, DSM 13114)
- the zwa2 gene which codes for the Zwa2 protein (DE: 19959327.2, DSM 13113)

to be attenuated at the same time.

In addition to attenuation of the citB gene it may furthermore be advantageous, for the production of amino acids, in particular L-lysine, to eliminate undesirable side reactions, (Nakayama: "Breeding of Amino Acid
5 Producing Micro-organisms", in: Overproduction of Microbial Products, Krumphanzl, Sikyta, Vanek (eds.), Academic Press, London, UK, 1982).

The invention also provides the microorganisms prepared according to the invention, and these can be cultured
10 continuously or discontinuously in the batch process (batch culture) or in the fed batch (feed process) or repeated fed batch process (repetitive feed process) for the purpose of production of L-amino acids, in particular L-lysine. A summary of known culture methods is described in the
15 textbook by Chmiel (Bioprozesstechnik 1. Einführung in die Bioverfahrenstechnik (Gustav Fischer Verlag, Stuttgart, 1991)) or in the textbook by Storhas (Bioreaktoren und periphere Einrichtungen (Vieweg Verlag, Braunschweig/Wiesbaden, 1994)).

20 The culture medium to be used must meet the requirements of the particular strains in a suitable manner. Descriptions of culture media for various microorganisms are contained in the handbook "Manual of Methods for General Bacteriology" of the American Society for Bacteriology
25 (Washington D.C., USA, 1981). Sugars and carbohydrates, such as e.g. glucose, sucrose, lactose, fructose, maltose, molasses, starch and cellulose, oils and fats, such as, for example, soya oil, sunflower oil, groundnut oil and coconut fat, fatty acids, such as, for example, palmitic acid,
30 stearic acid and linoleic acid, alcohols, such as, for example, glycerol and ethanol, and organic acids, such as, for example, acetic acid, can be used as the source of carbon. These substances can be used individually or as a mixture.

Organic nitrogen-containing compounds, such as peptones, yeast extract, meat extract, malt extract, corn steep liquor, soya bean flour and urea, or inorganic compounds, such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate, can be used as the source of nitrogen. The sources of nitrogen can be used individually or as a mixture.

Phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts can be used as the source of phosphorus. The culture medium must furthermore comprise salts of metals, such as, for example, magnesium sulfate or iron sulfate, which are necessary for growth. Finally, essential growth substances, such as amino acids and vitamins, can be employed in addition to the abovementioned substances. Suitable precursors can moreover be added to the culture medium. The starting substances mentioned can be added to the culture in the form of a single batch, or can be fed in during the culture in a suitable manner.

Basic compounds, such as sodium hydroxide, potassium hydroxide, ammonia or aqueous ammonia, or acid compounds, such as phosphoric acid or sulfuric acid, can be employed in a suitable manner to control the pH of the culture. Antifoams, such as, for example, fatty acid polyglycol esters, can be employed to control the development of foam. Suitable substances having a selective action, such as, for example, antibiotics, can be added to the medium to maintain the stability of plasmids. To maintain aerobic conditions, oxygen or oxygen-containing gas mixtures, such as, for example, air, are introduced into the culture. The temperature of the culture is usually 20°C to 45°C, and preferably 25°C to 40°C. Culturing is continued until a maximum of the desired product has formed. This target is usually reached within 10 hours to 160 hours.

Methods for the determination of L-amino acids are known from the prior art. The analysis can thus be carried out, for example, as described by Spackman et al. (Analytical Chemistry, 30, (1958), 1190) by anion exchange

5 chromatography with subsequent ninhydrin derivatization, or it can be carried out by reversed phase HPLC, for example as described by Lindroth et al. (Analytical Chemistry (1979) 51: 1167-1174).

The invention furthermore relates to a process for the
10 fermentative preparation of an amino acid chosen from the group consisting of L-asparagine, L-threonine, L-serine, L-glutamate, L-glycine, L-alanine, L-cysteine, L-valine, L-methionine, L-isoleucine, L-leucine, L-tyrosine, L-phenylalanine, L-histidine, L-lysine, L-tryptophan and L-
15 arginine, in particular L-lysine, using coryneform bacteria which in particular already produce one or more of the amino acids mentioned.

The following microorganism was deposited on 23.08.2000 as a pure culture at the Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ = German Collection of
20 Microorganisms and Cell Cultures, Braunschweig, Germany) in accordance with the Budapest Treaty:

- Escherichia coli strain Top10/pCR2.1citBint as DSM 13672.

25 The present invention is explained in more detail in the following with the aid of embodiment examples.

The isolation of plasmid DNA from Escherichia coli and all techniques of restriction, Klenow and alkaline phosphatase treatment were carried out by the method of Sambrook et al.
30 (Molecular Cloning. A Laboratory Manual, 1989, Cold Spring Harbour Laboratory Press, Cold Spring Harbor, NY, USA). Methods for transformation of Escherichia coli are also described in this handbook.

The composition of the usual nutrient media, such as LB or TY medium, can also be found in the handbook by Sambrook et al.

Example 1

- 5 Preparation of a genomic cosmid gene library from *C. glutamicum* ATCC 13032

Chromosomal DNA from *C. glutamicum* ATCC 13032 was isolated as described by Tauch et al. (1995, Plasmid 33:168-179) and partly cleaved with the restriction enzyme Sau3AI (Amersham
10 Pharmacia, Freiburg, Germany, Product Description Sau3AI, Code no. 27-0913-02). The DNA fragments were dephosphorylated with shrimp alkaline phosphatase (Roche Molecular Biochemicals, Mannheim, Germany, Product Description SAP, Code no. 1758250). The DNA of the cosmid
15 vector SuperCos1 (Wahl et al. (1987), Proceedings of the National Academy of Sciences, USA 84:2160-2164), obtained from Stratagene (La Jolla, USA, Product Description SuperCos1 Cosmid Vector Kit, Code no. 251301) was cleaved with the restriction enzyme XbaI (Amersham Pharmacia,
20 Freiburg, Germany, Product Description XbaI, Code no. 27-0948-02) and likewise dephosphorylated with shrimp alkaline phosphatase.

The cosmid DNA was then cleaved with the restriction enzyme BamHI (Amersham Pharmacia, Freiburg, Germany, Product
25 Description BamHI, Code no. 27-0868-04). The cosmid DNA treated in this manner was mixed with the treated ATCC13032 DNA and the batch was treated with T4 DNA ligase (Amersham Pharmacia, Freiburg, Germany, Product Description T4-DNA-Ligase, Code no.27-0870-04). The ligation mixture was then
30 packed in phages with the aid of Gigapack II XL Packing Extract (Stratagene, La Jolla, USA, Product Description Gigapack II XL Packing Extract, Code no. 200217).

For infection of the E. coli strain NM554 (Raleigh et al. 1988, Nucleic Acid Res. 16:1563-1575) the cells were taken up in 10 mM MgSO₄ and mixed with an aliquot of the phage suspension. The infection and titering of the cosmid library were carried out as described by Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor), the cells being plated out on LB agar (Lennox, 1955, Virology, 1:190) + 100 µg/ml ampicillin. After incubation overnight at 37°C, recombinant individual clones were selected.

Example 2

Isolation and sequencing of the citB gene

The cosmid DNA of an individual colony was isolated with the Qiaprep Spin Miniprep Kit (Product No. 27106, Qiagen, Hilden, Germany) in accordance with the manufacturer's instructions and partly cleaved with the restriction enzyme Sau3AI (Amersham Pharmacia, Freiburg, Germany, Product Description Sau3AI, Product No. 27-0913-02). The DNA fragments were dephosphorylated with shrimp alkaline phosphatase (Roche Molecular Biochemicals, Mannheim, Germany, Product Description SAP, Product No. 1758250). After separation by gel electrophoresis, the cosmid fragments in the size range of 1500 to 2000 bp were isolated with the QiaExII Gel Extraction Kit (Product No. 20021, Qiagen, Hilden, Germany).

The DNA of the sequencing vector pZero-1, obtained from Invitrogen (Groningen, The Netherlands, Product Description Zero Background Cloning Kit, Product No. K2500-01) was cleaved with the restriction enzyme BamHI (Amersham Pharmacia, Freiburg, Germany, Product Description BamHI, Product No. 27-0868-04). The ligation of the cosmid fragments in the sequencing vector pZero-1 was carried out as described by Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor), the DNA mixture

being incubated overnight with T4 ligase (Pharmacia Biotech, Freiburg, Germany). This ligation mixture was then electroporated (Tauch et al. 1994, FEMS Microbiol Letters, 123:343-7) into the E. coli strain DH5 α MCR (Grant, 1990, 5 Proceedings of the National Academy of Sciences, U.S.A., 87:4645-4649) and plated out on LB agar (Lennox, 1955, Virology, 1:190) with 50 μ g/ml zeocin.

The plasmid preparation of the recombinant clones was carried out with the Biorobot 9600 (Product No. 900200, 10 Qiagen, Hilden, Germany). The sequencing was carried out by the dideoxy chain termination method of Sanger et al. (1977, Proceedings of the National Academies of Sciences, U.S.A., 74:5463-5467) with modifications according to Zimmermann et al. (1990, Nucleic Acids Research, 18:1067). 15 The "RR dRhodamin Terminator Cycle Sequencing Kit" from PE Applied Biosystems (Product No. 403044, Weiterstadt, Germany) was used. The separation by gel electrophoresis and analysis of the sequencing reaction were carried out in a "Rotiphoresis NF Acrylamide/Bisacrylamide" Gel (29:1) 20 (Product No. A124.1, Roth, Karlsruhe, Germany) with the "ABI Prism 377" sequencer from PE Applied Biosystems (Weiterstadt, Germany).

The raw sequence data obtained were then processed using the Staden program package (1986, Nucleic Acids Research, 25 14:217-231) version 97-0. The individual sequences of the pZerol derivatives were assembled to a continuous contig. The computer-assisted coding region analyses were prepared with the XNIP program (Staden, 1986, Nucleic Acids Research, 14:217-231). Further analyses were carried out 30 with the "BLAST search program" (Altschul et al., 1997, Nucleic Acids Research, 25:3389-3402) against the non-redundant databank of the "National Center for Biotechnology Information" (NCBI, Bethesda, MD, USA).

The resulting nucleotide sequence is shown in SEQ ID No. 1. 35 Analysis of the nucleotide sequence showed an open reading

frame of 657 base pairs, which was called the citB gene.
The citB gene codes for a polypeptide of 219 amino acids.

Example 3

Preparation of an integration vector for integration
5 mutagenesis of the citB gene

From the strain ATCC 13032, chromosomal DNA was isolated by
the method of Eikmanns et al. (Microbiology 140: 1817 -
1828 (1994)). On the basis of the sequence of the citB gene
known for *C. glutamicum* from example 2, the following
10 oligonucleotides were chosen for the polymerase chain
reaction (see SEQ ID No. 4 and SEQ ID No. 5):

citB-int1:

5' CCC GGA TCT CCT ACT TGT TG 3'

citB-int2:

15 5' TCT GTG GCG GAT CTA GAG AC 3'

The primers shown were synthesized by MWG Biotech
(Ebersberg, Germany) and the PCR reaction was carried out
by the standard PCR method of Innis et al. (PCR protocols.
A guide to methods and applications, 1990, Academic Press)
20 with the Taq-polymerase from Boehringer Mannheim (Germany,
Product Description Taq DNA polymerase, Product No. 1 146
165). With the aid of the polymerase chain reaction, the
primers allow amplification of an internal fragment of the
citB gene 318 bp in size. The product amplified in this way
25 was tested electrophoretically in a 0.8% agarose gel.

The amplified DNA fragment (see SEQ ID No. 3) was ligated
with the TOPO TA Cloning Kit from Invitrogen Corporation
(Carlsbad, CA, USA; Catalogue Number K4500-01) in the
vector pCR2.1-TOPO (Mead et al. (1991) Bio/Technology
30 9:657-663).

The *E. coli* strain TOP10 was then electroporated with the
ligation batch (Hanahan, In: DNA cloning. A practical

approach. Vol.I. IRL-Press, Oxford, Washington DC, USA, 1985). Selection of plasmid-carrying cells was carried out by plating out the transformation batch on LB Agar (Sambrook et al., Molecular cloning: a laboratory manual. 2nd Ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), which had been supplemented with 50 mg/l kanamycin. Plasmid DNA was isolated from a transformant with the aid of the QIAprep Spin Miniprep Kit from Qiagen and checked by restriction with the restriction enzyme EcoRI and subsequent agarose gel electrophoresis (0.8%). The plasmid was called pCR2.1citBint and is shown in figure 1.

Example 4

Integration mutagenesis of the citB gene in the strains DSM 5715 and FERM-BP 1763

The vector pCR2.1citBint mentioned in example 3 was electroporated by the electroporation method of Tauch et al. (FEMS Microbiological Letters, 123:343-347 (1994)) into the strains *Corynebacterium glutamicum* DSM 5715 and *Brevibacterium lactofermentum* FERM-BP 1763. The strain DSM 5715 is an AEC-resistant lysine producer (EP-B-0435132), and the strain FERM-BP 1763 is a mycophenolic acid-resistant valine producer (US-A-5,188,948). The vector pCR2.1citBint cannot replicate independently in DSM5715 and FERM-BP 1763 and is retained in the cell only if it has integrated into the chromosome of DSM 5715 or FERM-BP 1763. Selection of clones with pCR2.1citBint integrated into the chromosome was carried out by plating out the electroporation batch on LB agar (Sambrook et al., Molecular cloning: a laboratory manual. 2nd Ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.), which had been supplemented with 15 mg/l kanamycin.

For detection of the integration, the citBint fragment was labelled with the Dig hybridization kit from Boehringer by

the method of "The DIG System Users Guide for Filter Hybridization" of Boehringer Mannheim GmbH (Mannheim, Germany, 1993). Chromosomal DNA of in each case a potential integrant was isolated by the method of Eikmanns et al. 5 (Microbiology 140: 1817 - 1828 (1994)) and in each case cleaved with the restriction enzymes EcoRI, BamHI and HindIII. The fragments formed were separated by means of agarose gel electrophoresis and hybridized at 68°C with the Dig hybridization kit from Boehringer. The plasmid 10 pCR2.1citBint mentioned in example 3 had been inserted into the chromosome of DSM5715 and into the chromosome of FERM-BP 1763 within the chromosomal citB gene. The strains were called DSM5715::pCR2.1citBint and FERM-BP 1763::pCR2.1citBint.

15 Example 5

Preparation of lysine

The *C.glutamicum* strain DSM5715::pCR2.1citBint obtained in example 4 was cultured in a nutrient medium suitable for the production of lysine and the lysine content in the 20 culture supernatant was determined.

For this, the strain was first incubated on an agar plate with the corresponding antibiotic (brain-heart agar with kanamycin (25 mg/l) for 24 hours at 33°C. Starting from this agar plate culture, a preculture was seeded (10 ml 25 medium in a 100 ml conical flask). The complete medium CgIII was used as the medium for the preculture.

Medium Cg III

NaCl	2.5 g/l
Bacto-Peptone	10 g/l
Bacto-Yeast extract	10 g/l
Glucose (autoclaved separately)	2% (w/v)

The pH is brought to pH 7.4

Kanamycin (25 mg/l) was added to this. The preculture was incubated for 16 hours at 33°C at 240 rpm on a shaking
5 machine. A main culture was seeded from this preculture such that the initial OD (660 nm) of the main culture is 0.1 OD. The medium MM-L was used for the main culture.

Medium MM-L

CSL (corn steep liquor)	5 g/l
MOPS (morpholinopropanesulfonic acid)	20 g/l
Glucose (autoclaved separately)	50g/l
Salts:	
$(\text{NH}_4)_2\text{SO}_4$	25 g/l
KH_2PO_4	0.1 g/l
$\text{MgSO}_4 * 7 \text{ H}_2\text{O}$	1.0 g/l
$\text{CaCl}_2 * 2 \text{ H}_2\text{O}$	10 mg/l
$\text{FeSO}_4 * 7 \text{ H}_2\text{O}$	10 mg/l
$\text{MnSO}_4 * \text{H}_2\text{O}$	5.0mg/l
Biotin (sterile-filtered)	0.3 mg/l
Thiamine * HCl (sterile-filtered)	0.2 mg/l
Leucine (sterile-filtered)	0.1 g/l
CaCO_3	25 g/l

The CSL, MOPS and the salt solution were brought to pH 7 with aqueous ammonia and autoclaved. The sterile
5 substrate, amino acid and vitamin solutions, as well as the CaCO_3 autoclaved in the dry state were then added.

Culturing was carried out in a 10 ml volume in a 100 ml conical flask with baffles. Kanamycin (25 mg/l) was added. Culturing was carried out at 33°C and 80% atmospheric
10 humidity.

After 72 hours, the OD was determined at a measurement wavelength of 660 nm with a Biomek 1000 (Beckmann Instruments GmbH, Munich). The amount of lysine formed was determined with an amino acid analyzer from Eppendorf-
5 BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column derivatization with ninhydrin detection.

The result of the experiment is shown in table 1.

Table 1

Strain	OD (660 nm)	Lysine HCl g/l
DSM5715	7.5	13.3
DSM5715::pCR2.1citBint	7.6	14.4

10 Example 6

Preparation of valine

The *B. lactofermentum* strain FERM-BP 1763::pCR2.1citBint obtained in example 4 was cultured in a nutrient medium suitable for the production of valine and the valine
15 content in the culture supernatant was determined.

For this, the strain was first incubated on an agar plate with the corresponding antibiotic (brain-heart agar with kanamycin (25 mg/l) for 24 hours at 33°C. Starting from this agar plate culture, a preculture was seeded (10 ml
20 medium in a 100 ml conical flask). The complete medium CgIII was used as the medium for the preculture. Kanamycin (25 mg/l) was added to this. The preculture was incubated for 16 hours at 33°C at 240 rpm on a shaking machine. A main culture was seeded from this preculture such that the

initial OD (660nm) of the main culture was 0.1 OD. The medium MM-V was used for the main culture.

Medium MM-V

CSL (corn steep liquor)	5 g/l
MOPS (morpholinopropanesulfonic acid)	20 g/l
Glucose (autoclaved separately)	50g/l
Salts:	
(NH ₄) ₂ SO ₄	25 g/l
KH ₂ PO ₄	0.1 g/l
MgSO ₄ * 7 H ₂ O	1.0 g/l
CaCl ₂ * 2 H ₂ O	10 mg/l
FeSO ₄ * 7 H ₂ O	10 mg/l
MnSO ₄ * H ₂ O	5.0mg/l
Isoeucine (sterile-filtered)	0.1 g/l
Methionine (sterile-filtered)	0.1 g/l
Thiamine * HCl (sterile-filtered)	0.2 mg/l
Leucine (sterile-filtered)	0.1 g/l
CaCO ₃	25 g/l

- 5 The CSL (corn steep liquor), MOPS
(morpholinopropanesulfonic acid) and the salt solution were
brought to pH 7 with aqueous ammonia and autoclaved. The
sterile substrate, amino acid and vitamin solutions, as
well as the CaCO₃ autoclaved in the dry state were then
10 added.

Culturing was carried out in a 10 ml volume in a 100 ml conical flask with baffles. Kanamycin (25 mg/l) was added. Culturing was carried out at 33°C and 80% atmospheric humidity.

- 5 After 48 hours, the OD was determined at a measurement wavelength of 660 nm with a Biomek 1000 (Beckmann Instruments GmbH, Munich). The amount of valine formed was determined with an amino acid analyzer from Eppendorf-BioTronik (Hamburg, Germany) by ion exchange chromatography
10 and post-column derivatization with ninhydrin detection.

The result of the experiment is shown in table 2.

Table 2

Strain	OD (660 nm)	Valine HCl g/l
FERM-BP 1763	12.1	7.5
FERM-BP 1763::pCR2.1citBint	13.3	11.3

Brief Description of the Figure:

- 15 Figure 1: Map of the plasmid pCR2.1citBint.

The abbreviations and designations used have the following meaning.

KmR: Kanamycin resistance gene

EcoRI: Cleavage site of the restriction enzyme
EcoRI

HindIII: Cleavage site of the restriction enzyme
HindIII

BamHI: Cleavage site of the restriction enzyme
BamHI

citBint: Internal fragment of the citB gene

ColE1: Replication origin of the plasmid ColE1

What is claimed is:

1. Isolated polynucleotide from coryneform bacteria,
comprising a polynucleotide sequence which codes for
the citB gene, chosen from the group consisting of
 - 5 a) polynucleotide which is identical to the extent of
at least 70 % to a polynucleotide which codes for a
polypeptide which comprises the amino acid sequence
of SEQ ID No. 2,
 - 10 b) polynucleotide which codes for a polypeptide which
comprises an amino acid sequence which is identical
to the extent of at least 70% to the amino acid
sequence of SEQ ID No. 2,
 - c) polynucleotide which is complementary to the
polynucleotides of a) or b), and
 - 15 d) polynucleotide comprising at least 15 successive
nucleotides of the polynucleotide sequence of a),
b), or c),

the polypeptide preferably having the activity of
the transcription regulator CitB.
- 20 2. Polynucleotides according to claim 1, wherein the
polynucleotide is a preferably recombinant DNA which
is capable of replication in coryneform bacteria.
3. Polynucleotides according to claim 1, wherein the
polynucleotide is an RNA.
- 25 4. Polynucleotide according to claim 2, comprising the
nucleic acid sequence as shown in SEQ ID No. 1.
5. DNA according to claim 2 which is capable of
replication, comprising


- (i) the nucleotide sequence shown in SEQ ID No. 1,
or
 - (ii) at least one sequence which corresponds to
sequence (i) within the range of the
5 degeneration of the genetic code, or
 - (iii) at least one sequence which hybridizes with the
sequences complementary to sequences (i) or
(ii), and optionally
 - (iv) sense mutations of neutral function in (i).
- 10 6. DNA according to claim 5, wherein the hybridization is
carried out under a stringency corresponding to at
most 2x SSC.
7. Polynucleotide sequence according to claim 2, which
codes for a polypeptide which comprises the amino acid
15 sequence shown in SEQ ID No. 2.
8. The vector pCR2.1citBint, which
- 8.1. carries an internal fragment of the citB gene
318 bp in size, shown in SEQ ID. No. 3,
 - 8.2 the restriction map of which is reproduced in
20 figure 1, and
 - 8.3 which is deposited in the E. coli strain
Top10/pCR2.1citBint under no. DSM 13672 at the
Deutsche Sammlung für Mikroorganismen und
Zellenkulturen [German Collection of
25 Microorganisms and Cell Cultures].
9. Internal fragment of the citB gene with a length of
318 bp, shown in SEQ ID No. 3.
10. Coryneform bacteria, in which the citB gene is
attenuated, preferably eliminated.

11. Process for the preparation of L-amino acids, in particular L-lysine, wherein the following steps are carried out
 - a) fermentation of the coryneform bacteria which produce the desired L-amino acid and in which at least the citB gene is attenuated,
 - b) concentration of the desired product in the medium or in the cells of the bacteria and
 - c) isolation of the L-amino acid.
12. Process according to claim 11, wherein bacteria in which further genes of the biosynthesis pathway of the desired L-amino acid are additionally enhanced are employed.
13. Process according to claim 11, wherein bacteria in which the metabolic pathways which reduce the formation of the desired L-amino acid are at least partly eliminated are employed.
14. Process according to claim 11, wherein the expression of the polynucleotide(s) which codes (code) for the citB gene is decreased, in particular eliminated.
15. Process according to claim 11, wherein the regulatory or catalytic properties of the polypeptide for which the polynucleotide citB codes are decreased.
16. Process according to claim 11, wherein for the preparation of L-amino acids, in particular L-lysine, bacteria in which at the same time one or more of the genes chosen from the group consisting of
 - 16.1 the dapA gene which codes for dihydrodipicolinate synthase,
 - 16.2 the gap gene which codes for glyceraldehyde 3-phosphate dehydrogenase

- 16.3 the zwf gene which codes for glucose 6-phosphate dehydrogenase,
- 16.4 the pyc gene which codes for pyruvate carboxylase,
- 16.5 the lysE gene which codes for lysine export,
- 5 16.6 the lysC gene which codes for a feed back resistant aspartate kinase,
- 16.7 the zwal gene which codes for the Zwal protein is or are enhanced, preferably over-expressed, are fermented.
- 10 17. Process according to claim 11, wherein at the same time one or more of the genes chosen from the group consisting of:
- 17.1 the pck gene which codes for phosphoenol pyruvate carboxykinase,
- 15 17.2 the pgi gene which codes for glucose 6-phosphate isomerase,
- 17.3 the poxB gene which codes for pyruvate oxidase,
- 17.4 the zwa2 gene which codes for the Zwa2 protein is or are attenuated.
- 20 18. Coryneform bacteria which contain a vector which carries parts of the polynucleotide, but at least 15 successive nucleotides of the sequence according to claim 1.
19. Process according to one or more of the preceding
25 claims, wherein microorganisms of the genus Corynebacterium are employed.

20. Process for discovering RNA, cDNA and DNA in order to isolate nucleic acids, or polynucleotides or genes which code for the transcription regulator CitB or have a high similarity with the sequence of the citB gene, wherein the polynucleotide sequences according to claim 1 to 4 are employed as hybridization probes.
21. Process according to claim 20, wherein arrays, micro arrays or DNA chips are employed.

Figure 1: Plasmid pCR2.1citBint



SEQUENCE PROTOCOL

<110> Degussa AG

<120> Nucleotide sequences which code for the citB gene

<130> 000171 BT

<140>

<141>

<160> 5

<170> PatentIn Ver. 2.1

<210> 1

<211> 1056

<212> DNA

<213> Corynebacterium glutamicum

<220>

<221> CDS

<222> (201)..(854)

<223> citB gene

<400> 1

```

atcccagagg gcgtggatgt atttgccaca gccacccaga taggagactc tgaagataat 60
gaacgcaccc acgggcatgg cattggtcta aaactgtgcc gggctttggc tagatcacat 120
ggtggcgatg tctgggtgat tgatagagga accgaagatg gcgctgtatt tggagtgaaa 180
ctaccgggag taatggagta atg gat caa aca ctt aaa gtt tta gta att gat 233
                Met Asp Gln Thr Leu Lys Val Leu Val Ile Asp
                1             5             10

gat gat ttc cgc gtc gcc ggc att cac gcc tcc atc gtt gat gcg tcc 281
Asp Asp Phe Arg Val Ala Gly Ile His Ala Ser Ile Val Asp Ala Ser
                15             20             25

cct gga ttt tcg gtg gtc ggt acc gcg cgt acc ctc gca gag gca aaa 329
Pro Gly Phe Ser Val Val Gly Thr Ala Arg Thr Leu Ala Glu Ala Lys
                30             35             40

acc ctg atc gcc aca ttt tcc ccg gat ctc cta ctt gtt gat gtc tac 377
Thr Leu Ile Ala Thr Phe Ser Pro Asp Leu Leu Leu Val Asp Val Tyr
                45             50             55

ctc ccc gac ggc gat ggc att gac ctc gtg ggc acc tcc aat att gat 425
Leu Pro Asp Gly Asp Gly Ile Asp Leu Val Gly Thr Ser Asn Ile Asp
                60             65             70             75

gcg ttt gtg ctc agc gca gcc gat gac atc aaa aca gtt cga cgc gcc 473
Ala Phe Val Leu Ser Ala Ala Asp Asp Ile Lys Thr Val Arg Arg Ala
                80             85             90

atg cgt gcc ggg gca ctc gga tat ctg ctc aaa cca ttt ccc caa aaa 521
Met Arg Ala Gly Ala Leu Gly Tyr Leu Leu Lys Pro Phe Pro Gln Lys
                95             100             105

```

5 cgt ctc gtg gaa cgc ctt gac cgt tac gtc cgc tac cgc cat gtc tta 569
 Arg Leu Val Glu Arg Leu Asp Arg Tyr Val Arg Tyr Arg His Val Leu
 110 115 120

10 tcc ggc acc caa gga ctt tcc caa gac aaa att gac cag gca acc gca 617
 Ser Gly Thr Gln Gly Leu Ser Gln Asp Lys Ile Asp Gln Ala Thr Ala
 125 130 135

15 atc ctc aac ggc acc caa gcg ccg gtc acc gtc tot aga tcc gcc aca 665
 Ile Leu Asn Gly Thr Gln Ala Pro Val Thr Val Ser Arg Ser Ala Thr
 140 145 150 155

20 gag caa tta ctt ctc gac gcc ctg gaa ggc caa gaa ctc tcc gca aca 713
 Glu Gln Leu Leu Leu Asp Ala Leu Glu Gly Gln Glu Leu Ser Ala Thr
 160 165 170

25 gaa gct tcc gaa gct gcc gga gtt tca cgt gcc aca gca cag cgc agg 761
 Glu Ala Ser Glu Ala Ala Gly Val Ser Arg Ala Thr Ala Gln Arg Arg
 175 180 185

30 ctg gca gcg atg gct agc caa ggt gtg atc cag gtt cgc ctt cgg tac 809
 Leu Ala Ala Met Ala Ser Gln Gly Val Ile Gln Val Arg Leu Arg Tyr
 190 195 200

35 gga cag tcc ggg cga cca gaa cat cta tat tca aag cca ctg ctc 854
 Gly Gln Ser Gly Arg Pro Glu His Leu Tyr Ser Lys Pro Leu Leu
 205 210 215

40 tagtaacctt tgtggatgtc cacctcggtc agcatctttt ctccagcgag aaaccgtcgg 914
 tagttttctg ccaccactgg ggcaagcatg cgatccatcg aggtcaacgt gttggctacg 974
 tgcggggtaa tgatcacatt gctgcgcccc cacagtggat gatcggtcgg caatggttca 1034
 ggatcgggtga catctaagcc tg 1056

<210> 2
 <211> 218
 <212> PRT
 <213> *Corynebacterium glutamicum*

45 <400> 2
 Met Asp Gln Thr Leu Lys Val Leu Val Ile Asp Asp Asp Phe Arg Val
 1 5 10 15

50 Ala Gly Ile His Ala Ser Ile Val Asp Ala Ser Pro Gly Phe Ser Val
 20 25 30

55 Val Gly Thr Ala Arg Thr Leu Ala Glu Ala Lys Thr Leu Ile Ala Thr
 35 40 45

60 Phe Ser Pro Asp Leu Leu Leu Val Asp Val Tyr Leu Pro Asp Gly Asp
 50 55 60

65 Gly Ile Asp Leu Val Gly Thr Ser Asn Ile Asp Ala Phe Val Leu Ser
 65 70 75 80

Ala Ala Asp Asp Ile Lys Thr Val Arg Arg Ala Met Arg Ala Gly Ala
85 90 95

5 Leu Gly Tyr Leu Leu Lys Pro Phe Pro Gln Lys Arg Leu Val Glu Arg
100 105 110

Leu Asp Arg Tyr Val Arg Tyr Arg His Val Leu Ser Gly Thr Gln Gly
115 120 125

10 Leu Ser Gln Asp Lys Ile Asp Gln Ala Thr Ala Ile Leu Asn Gly Thr
130 135 140

Gln Ala Pro Val Thr Val Ser Arg Ser Ala Thr Glu Gln Leu Leu Leu
145 150 155 160

15 Asp Ala Leu Glu Gly Gln Glu Leu Ser Ala Thr Glu Ala Ser Glu Ala
165 170 175

20 Ala Gly Val Ser Arg Ala Thr Ala Gln Arg Arg Leu Ala Ala Met Ala
180 185 190

Ser Gln Gly Val Ile Gln Val Arg Leu Arg Tyr Gly Gln Ser Gly Arg
195 200 205

25 Pro Glu His Leu Tyr Ser Lys Pro Leu Leu
210 215

30 <210> 3
<211> 318
<212> DNA
<213> Corynebacterium glutamicum

35 <220>
<223> citBint

<400> 3

40 cccggatctc ctacttggtg atgtctacct ccccgacggc gatggcattg acctcgtggg 60
cacctccaat attgatgcgt ttgtgctcag cgcagccgat gacatcaaaa cagttcgacg 120
cgccatgcgt gccggggcac tcggatatct gctcaaacca ttccccaaa aacgtctcgt 180
ggaacgcctt gaccgttacg tccgctaccg ccatgtctta tccggcaccc aaggactttc 240
ccaagacaaa attgaccagg caaccgcaat cctcaacggc acccaagcgc cggtcaccgt 300
ctctagatcc gccacaga 318

45

<210> 4
<211> 20
<212> DNA
50 <213> Corynebacterium glutamicum

<220>
<223> Primer citB-int1

55 <400> 4
cccggatctc ctacttggtg 20

<210> 5

<211> 20
<212> DNA
<213> Corynebacterium glutamicum
5 <220>
<223> Primer citB-int2
<400> 5
10 tctgtggcgg atctagagac 20

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N15/31 C12N15/77 C12P13/04 C12P13/08 //C12R1/15		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N C12P		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EMBL, EPO-Internal, WPI Data, BIOSIS, CHEM ABS Data, MEDLINE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DATABASE SWALL 'Online! Accession number Q9RC52, 1 May 2000 (2000-05-01) HIDETO, T. ET AL. : "CITT (Two-component response regulator)" XP002186605 the whole document -/--	1-21
☒ Further documents are listed in the continuation of box C. ☒ Patent family members are listed in annex.		
* Special categories of cited documents :		
A document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Z* document member of the same patent family		
Date of the actual completion of the international search 7 January 2002		Date of mailing of the international search report 22/01/2002
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Montero Lopez, B

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/08387

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	EP 1 108 790 A (KYOWA HAKKO KOGYO CO., LTD.) 20 June 2001 (2001-06-20) page 3, line 3 - line 13 page 3, line 40 -page 5, line 5; example 1 Table 1, page 39, SEQ ID NO:79	1,2,4-7, 9,18,20, 21
P,X	& DATABASE EMBL 'Online! Accession number AX120163, 10 May 2001 (2001-05-10) NAKAGAWA S. ET AL.: "Sequence 79 from Patent EP1108790" the whole document	1,2,5,6, 9
P,X	& DATABASE EMBL 'Online! Accession number AX120085, 10 May 2001 (2001-05-10) NAKAGAWA S. ET AL.: "Sequence 1 from Patent EP1108790" nucleotides 71960-73020	1,2,4-7, 9
P,X	WO 01 00844 A (BASF AKTIENGESellschaft) 4 January 2001 (2001-01-04) page 10, line 25 -page 11, line 6 page 22, line 25 -page 28, line 15 Table 1, page 61, SEQ ID NO:143 page 45, line 27 -page 51, line 14	1,5,18, 20,21

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC1/EP 01/08387

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 1108790	A	20-06-2001	EP 1108790 A2	20-06-2001
WO 0100844	A	04-01-2001	AU 5559000 A	31-01-2001
			WO 0100844 A2	04-01-2001
			WO 0100843 A2	04-01-2001
			AU 5836900 A	31-01-2001
			WO 0100804 A2	04-01-2001
			AU 5421300 A	31-01-2001
			AU 5421600 A	31-01-2001
			WO 0100805 A2	04-01-2001
			AU 5420500 A	31-01-2001
			WO 0100842 A2	04-01-2001
			AU 5701400 A	22-01-2001
			WO 0102583 A2	11-01-2001